Yin Shengyong, Li Jinjun, Hu Chen, Chen Xinhua, Yao Ming, Yan Mingxia, Jiang Guoping, Ge Chao, Xie Haiyang, Wan Dafang, Yang Shengli, Zheng Shusen, Gu Jianren
Department of General Surgery, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, People's Republic of China.
Int J Cancer. 2007 Apr 1;120(7):1444-50. doi: 10.1002/ijc.22476.
Recently increasing reported data have suggested that only a small subset of cancer cells possess capability to initiate malignancies including leukemia and solid tumors, which was based on investigation in these cells displaying a distinct surface marker pattern within the primary cancers. CD133 is a putative hematopoietic and neuronal stem-cell marker, which was also considered as a tumorigenic marker in brain and prostate cancer. We hypothesized that CD133 was a marker closely correlated with tumorigenicity, since it was reported that CD133 expressed in human fetal liver and repairing liver tissues, which tightly associated with hepatocarcinogenesis. Our findings showed that a small population of CD133 positive cells indeed exists in human hepatocellular carcinoma (HCC) cell lines and primary HCC tissues. From SMMC-7721 cell line, CD133+ cells isolated by MACS manifested high tumorigenecity and clonogenicity as compared with CD133- HCC cells. The implication that CD133 might be one of the markers for HCC cancer stem-like cells needed further investigation.
最近越来越多的报道数据表明,只有一小部分癌细胞具有引发恶性肿瘤(包括白血病和实体瘤)的能力,这是基于对这些在原发性癌症中表现出独特表面标志物模式的细胞的研究得出的。CD133是一种假定的造血和神经干细胞标志物,在脑癌和前列腺癌中也被视为致瘤标志物。我们推测CD133是一种与致瘤性密切相关的标志物,因为有报道称CD133在人胎儿肝脏和修复中的肝脏组织中表达,这与肝癌发生密切相关。我们的研究结果表明,在人肝癌(HCC)细胞系和原发性肝癌组织中确实存在一小部分CD133阳性细胞。与CD133阴性的肝癌细胞相比,通过磁珠分选法从SMMC-7721细胞系中分离出的CD133+细胞表现出高致瘤性和克隆形成能力。CD133可能是肝癌癌干细胞样细胞标志物之一这一观点需要进一步研究。